siRNAs: their potential as therapeutic agents – Part II. Methods of delivery
- 30 September 2009
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 14 (17-18) , 859-865
- https://doi.org/10.1016/j.drudis.2009.06.002
Abstract
No abstract availableKeywords
This publication has 99 references indexed in Scilit:
- Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammationNature, 2009
- T Cell-Specific siRNA Delivery Suppresses HIV-1 Infection in Humanized MiceCell, 2008
- Sequence- and target-independent angiogenesis suppression by siRNA via TLR3Nature, 2008
- Control of coleopteran insect pests through RNA interferenceNature Biotechnology, 2007
- Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primatesProceedings of the National Academy of Sciences, 2007
- Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNAProceedings of the National Academy of Sciences, 2007
- Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathwaysNature, 2006
- Recognition and cleavage of primary microRNA precursors by the nuclear processing enzyme DroshaThe EMBO Journal, 2004
- A resource for large-scale RNA-interference-based screens in mammalsNature, 2004
- A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined ImmunodeficiencyNew England Journal of Medicine, 2003